Status:
COMPLETED
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hypertension, Glaucoma, Open-Angle
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle gl...
Eligibility Criteria
Inclusion
- Adult patients, at least 21 years of age, inclusive
- Diagnosis of ocular hypertension or primary open angle glaucoma in at least one eye
- Able to participate and willing to give informed consent
Exclusion
- Presence of extreme narrow angle with complete or partial closure
- Progressive retinal or optic nerve disease from any cause other than glaucoma
- History or signs of penetrating ocular trauma
- Uncontrolled hypertension
- Clinically significant abnormalities in laboratory test results
- Positive test results on hepatitis B, hepatitis C, or HIV 1 and 2
- Kidney disease or dysfunction
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01493271
Start Date
December 1 2011
End Date
November 1 2012
Last Update
November 2 2016
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Morrow, Georgia, United States, 30260
2
High Point, North Carolina, United States, 27262
3
Mt. Pleasant, South Carolina, United States, 29464
4
Sofia, Bulgaria, 1517